A Novel Therapeutic Approach for High‑Risk and Relapsed/Refractory Neuroblastoma: Dinutuximab Beta
Dinutuximab beta shows promise as an effective and reliable option for treating high‑risk and relapsed/refractory neuroblastoma, with seven of eight patients surviving and only one death attributed to severe capillary leak syndrome.
Background: Survival of patients in the high‑risk group and those with relapsed/refractory neuroblastoma is significantly low. For these patients, results obtained with dinutuximab beta are promising. Objectives: We retrospectively analyzed our experience with dinutuximab beta in high‑risk and relapsed/refractory neuroblastoma. Methods: Dinutuximab beta was given alternating with 13‑cis retinoic acid as part of maintenance therapy for high‑risk patients, or with 13‑cis retinoic acid or a chemotherapy regimen for relapsed patients, with a continuous infusion at a dose of 10 mg/m²/day for 10 days. Results: Between March 2021 and February 2023, six patients were treated for high‑risk disease and two for relapsed disease with dinutuximab beta. Of all patients, seven are alive. One patient died due to severe capillary leak syndrome. Conclusions: Dinutuximab beta can be an effective and reliable option in addition to standard treatment for patients diagnosed with high‑risk and relapsed/refractory neuroblastoma compared with previous experience. However, especially in cases with pulmonary problems such as bronchopulmonary dysplasia, this drug should be carefully reassessed because of the irreversible adverse effect of capillary leak syndrome.
High‑risk neuroblastoma carries a poor prognosis; adding dinutuximab beta, an anti‑GD2 monoclonal antibody, may improve survival outcomes while highlighting the need for vigilant monitoring of potentially life‑threatening toxicities such as capillary leak syndrome.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Updates in Diagnosis, Management, and Treatment of Neuroblastoma
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Emerging clinical and research approaches in targeted therapies for high-risk neuroblastoma
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study